• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and Experimental Immunology: An Official Journal of the British Society for Immunology >Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer
【24h】

Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer

机译：前列腺癌患者中针对Engrailed-2（EN2）蛋白的自发抗体

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary: We reported the expression of the homeodomain-containing transcription factor Engrailed-2 (EN2) in prostate cancer and showed that the presence of EN2 protein in the urine was highly predictive of prostate cancer. This study aimed to determine whether patients with prostate cancer have EN2 autoantibodies, what the prevalence of these antibodies is and whether they are associated with disease stage. The spontaneous immunoglobulin (Ig)G immune response against EN2 and for comparison the tumour antigen New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1), were tested by enzyme-linked immunosorbent assay (ELISA) in three different cohorts of prostate cancer patients as well as a group of men genetically predisposed to prostate cancer. Thirty-two of 353 (9·1%) of the SUN cohort representing all stages of prostate cancer demonstrated EN2 IgG responses, 12 of 107 patients (11·2%) in the advanced prostate cancer patients showed responses, while only four of 121 patients (3·3%) with castrate-resistant prostate cancer showed EN2 autoantibodies. No significant responses were found in the predisposed group. Anti-EN2 IgG responses were significantly higher in patients with prostate cancer compared to healthy control males and similarly prevalent to anti-NY-ESO-1 responses. While EN2 autoantibodies are not a useful diagnostic or monitoring tool, EN2 immunogenicity provides the rationale to pursue studies using EN2 as an immunotherapeutic target.
机译：摘要：我们报道了含有同源结构域的转录因子Engrailed-2（EN2）在前列腺癌中的表达，并表明尿液中EN2蛋白的存在可高度预测前列腺癌。这项研究旨在确定前列腺癌患者是否患有EN2自身抗体，这些抗体的流行程度以及它们是否与疾病阶段相关。通过酶联免疫吸附测定（ELISA）在三个不同的前列腺癌人群中测试了针对EN2的自发性免疫球蛋白（Ig）G免疫反应以及作为比较的肿瘤抗原纽约食管鳞状细胞癌1（NY-ESO-1）患者以及一群在基因上易患前列腺癌的男性。代表前列腺癌所有阶段的353名SUN队列中有32名（9·1％）表现出EN2 IgG应答，晚期前列腺癌患者中107名患者中有12名（11·2％）表现出应答，而121名患者中只有4名去势抵抗性前列腺癌患者（3·3％）显示EN2自身抗体。在易感人群中未发现明显反应。与健康对照组男性相比，前列腺癌患者的抗EN2 IgG反应显着更高，并且与抗NY-ESO-1反应相似。尽管EN2自身抗体不是有用的诊断或监测工具，但EN2的免疫原性为进行以EN2作为免疫治疗靶标的研究提供了理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号